Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,056,941

« Back to Dashboard
Patent 6,056,941 protects CARDIOTEC and is included in one NDA.

This patent has ten patent family members in seven countries.

Summary for Patent: 6,056,941

Title: Kit for the preparation of technetium TC 99m teboroxime myocardial perfusion agent
Abstract:A kit containing a solution of boronic acid adducts of technetium-99 m dioxime complexes; and hydroxypropyl gamma cyclodextrin to maintain the solution free of particulate matter originating from the formulation.
Inventor(s): Schramm; Ernest (North Brunswick, NJ), Newborn; Margaret (Hamilton, NJ), Zodda; Julius P. (Mercerville, NJ), Katona; Thomas (Mercerville, NJ), Monteferrante; Jo Anna (Flemington, NJ)
Assignee: Bracco Research USA (Princeton, NJ)
Application Number:09/363,132
Patent Claim Types:
see list of patent claims
Device; Compound;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 10th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
technetium tc-99m teboroxime kit
INJECTABLE;INJECTION019928-001Dec 19, 1990DISCNNo6,056,941Jul 28, 2019Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,056,941

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
MexicoPA02000628► subscribe
Norway20020239► subscribe
Norway321254► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.